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Abstract
Objective The study investigated whether baseline plasma
oxytocin (OXT) concentrations might moderate the effects
of nasally administered OXT on social orienting.
Methods Thirty-one males with Autism spectrum disorder
(ASD) and thirty healthy males participated in a double-
blind placebo-controlled crossover trial. After administration
of the compound, participants were viewing pictures from the
International Affective Picture System that represented a sys-
tematic variation of pleasant, unpleasant and neutral scenes
with and without humans. The outcome measures were a car-
diac evoked response (ECR) and a cortical evoked long laten-
cy parietal positivity (LPP).
Results Males with ASD had significantly higher plasma
baseline levels than the controls. In the absence of general
treatment effects, higher baseline concentrations were found
to be associated with larger treatment effects, particularly in
the group of males with ASD. Higher post-treatment plasma
OXT concentrations were found to be associated with smaller
treatment effects and larger orienting responses in the placebo
situation in the group of controls.
Conclusions We interpret our findings as suggesting that it
is the central availability of OXT determining how much
of the nasally administered OXT will become centrally
absorbed and how much of it will become released into
the bloodstream.
Keywords Baseline plasma oxytocin . Post-oxytocin
treatment plasma oxytocin . Social orienting . Autism
spectrum disorder . Electrocortical and cardiac evoked
responses
Introduction
Following the many studies on the role of oxytocin (OXT) in
prosocial behaviour and attachment (see Bartz et al. 2011;
Guastella and MacLeod 2012; Bakermans-Kranenburg and
van I Jzendoorn 2013 for extensive reviews), OXT has in-
creasingly been investigated for its role in the pathophysiolo-
gy and potential treatment of the core deficits in autism spec-
trum disorders (ASD), especially since its nasal administration
has suggested some promising results (Andari et al. 2010;
Guastella et al. 2010). ASDs are characterized by deficits in
social communication and interaction as well as by restricted,
repetitive behaviours and interests (American Psychiatric
Association 2013).
In their review on ‘the role of oxytocin in psychiatric dis-
orders’, Cochran et al. (2013) highlighted three lines of inves-
tigation on which studies into the social effects of OXT have
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focused: (1) studies of endogenous peripheral (blood plasma,
urinary and salivary) and/or central (cerobrospinal fluid
[CSF]) OXT levels, (2) genetic studies and (3) exogenous
OXT administration studies. As the present study aimed at
investigating whether baseline OXT plasma levels are associ-
ated with the effect of nasally administered OXT on social
orienting in healthy male adults and male adults with ASD,
we have briefly summarized the main findings of the OXT
treatment studies conducted on people with ASD as well as
the main findings of studies investigating endogenous periph-
eral and central levels of OXT in a variety of clinical and non-
clinical groups.
The first randomized placebo-controlled studies on the
acute effects of exogenously administered OXTon the behav-
iour of individuals with ASD were those by Hollander and
colleagues (2003; 2007) who administered OXT by intrave-
nous infusion to adults with autism and Asperger’s disorder.
The experiments showed a greater reduction in repetitive be-
haviours during OXT infusion compared to placebo (2003)
and suggested improvements in affective speech comprehen-
sion (2007). In a subsequent study, Guastella et al. (2010)
administered OXT nasally to 12- to 19-year-old males with
autism or Asperger’s disorder and demonstrated improved
performance on the Reading the Mind in the-Eyes test
(RMET, Baron-Cohen et al 2001) that measures the ability
to infer the mood of a person from pictures where only the
eye regions of faces are shown. Furthermore, increased coop-
erative interaction and self-reported feelings of trust were
found after nasal administration in young adults with high-
functioning autism and Asperger’s disorder when playing a
computerized ball throwing game (Andari et al. 2010). These
improvements in social behaviour refer to capacities of mak-
ing inferences about another person’s mood or intention, i.e. to
capacities that are related to having a theory of the other’s
mind (ToM), the main ingredient for showing cognitive em-
pathy (e.g. Shamai-Tsoory 2011). In the study by Andari and
colleagues, moreover, increased fixation time was found on
the eye region of faces in pictures that had to be judged for
gender and gaze direction. Interestingly, this response to OXT
depended on the patients’ social interaction style. Most of the
patients who actively displayed approach behaviour, though
in an inappropriate or one-sided way, showed positive effects,
while most of the individuals who avoided or actively rejected
proximity with others showed no response to the treatment.
This indicated that the response to OXT may differ for sub-
groups of patients with ASD. Two longer-term trials have
been conducted administering OXT nasally twice daily for
6 weeks (Anagnostou et al. 2012) and once daily for four
consecutive days (Dadds et al. 2014) to adults and children
with ASD, respectively. Both studies found no significant
change in the primary outcome measures of general social
functioning and repetitive behaviours, i.e. the core features
of ASD. Although the first study found improvements in
emotion recognition as measured with the RMET as well as
in a broad measure of quality of life, there were no such find-
ings in the second study. The main conclusion by Dadds and
colleagues was therefore to be cautious in recommending na-
sal OXT as a general treatment for young people with autism.
This suggestion was corroborated by the findings of our
own study on the effects of nasally administered OXT on
social orienting in male adults with ASD (Althaus et al.
2015). In the first place, this study revealed no significant
treatment effects, neither in the group of healthy control males
nor in the group of males with ASD. However, moderator
analysis demonstrated that OXT did enhance social orienting
in male adults with ASD who are easily distressed when see-
ing others in stressful situations, and in healthy males who are
highly sensitive to anticipated punishment and criticism or
have a low drive for goal achievement. We concluded that
individual differences in stress-related avoidance tendencies
should be taken into account when considering OXT as a
treatment of social deficiencies in autism, which was in agree-
ment with what Dadds et al. (2014), Bartz et al. (2011), and
Andari et al. (2010) had previously pointed to, i.e. the person
and context dependency that might explain the inconsistencies
found in reported OXT effects.
Another moderator of OXT administration effects not yet
investigated as such might be the natural variation in endoge-
nous OXT levels. These natural variations are most often
measured in a peripheral medium such as blood plasma, urine
or saliva, given the discomfort and risks associatedwith taking
CSF by lumbar puncture. Hence, studies of CSF-OXT in
humans are scarce and therefore still little is known about
the relationship between the central and peripheral availability
and action of OXT.
Increased plasma and saliva levels of OXT have repeatedly
been found to be related to prosocial behaviour and hence
have been suggested to reflect central OXT effects. For exam-
ple, peripheral OXT levels were elevated in mothers after
interacting with their infants (Strathearn et al. 2009). Also,
higher plasma OXT levels during pregnancy in primaparous
women predicted higher quality of postpartummaternal bond-
ing behaviour (Feldman et al. 2007), while lower levels were
predictive of postnatal depression (Skrundz et al. 2011). In the
same line, lowered CSF-OXT levels were found in adult
women who had been exposed to childhood maltreatment
(Heim et al. 2009), and lowered urinary OXT levels were
found in children placed in orphanages shortly after birth
(Fries et al. 2005). Also in patients with schizophrenia, plasma
OXT levels were found to be lower than in healthy subjects,
while, in addition, lower levels were associated with more
psychotic symptoms (Rubin et al. 2010).
However, the relationship between peripheral OXT levels
and social function in ASD is not as straightforward as the
above studies would suggest. That is, while lower mean plas-
ma OXT levels were found in 6- to 11-year-old boys with
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autism compared to age matched healthy controls, elevated
OXT levels were associated with lower scores on the
Vineland Adaptive Behaviour Scale (VABS), which was re-
verse in the control group (Modahl et al. 1998; Green et al.
2001). This suggests that (high) OXT plasma levels are dif-
ferentially related to centrally controlled behaviour in autistic
vs. healthy children. Yet, in contrast to what has been found
for children with ASD, in a study comparing adults with ASD
to healthy control adults, baseline blood plasma levels were
shown to be significantly higher in the ASD group. In this
study, no correlations between plasma OXT levels and impair-
ments in social interactive behaviour were found (Jansen et al
2006). Different from the studies with children, however, the
adults were all high functioning while intellectual functioning
in the studies of children varied among the participants. This
suggests that the OXT system of individuals with ASD may
change during lifespan and that OXT plasma levels in ASD
may not only be related to developmental but also to intellec-
tual determinants (Jansen et al. 2006).
In summary, the majority of studies suggest that high plas-
ma OXT baseline levels are associated with prosocial skills
and behaviour. With regard to the moderating effects of plas-
ma OXT baseline levels on the effect of exogenously admin-
istered OXT on social behaviour, this might mean that indi-
viduals with lower baseline levels would benefit more from
OXT administration and hence show larger treatment effects
than those with higher baseline levels.
The present study used the data of our abovementioned
previous study showing that nasally administered OXT en-
hances social orienting in a selective group of male adults with
ASD (Althaus et al. 2015). While our previous study took into
account the OXT effect-moderating influences of personal
characteristics as assessed by questionnaires, the present study
investigated whether the baseline level of blood plasma OXT
influences the effect of nasally administered OXT on social
orienting. As in our previous study, social orienting was in-
vestigated by comparing neurophysiological responses to af-
fective pictures with and without social relevance. These re-
sponses were an evoked cardiac response (ECR, i.e. stimulus-
dependent heart rate slowing) and an event-related potential
(ERP) derived from the electroencephalogram (EEG), i.e. a
late long lasting parietal positivity (LPP). Both types of re-
sponses, in particular to the pictures with humans, have pre-
viously been shown to discriminate between men and women
(Proverbio et al. 2009; Groen et al. 2013; Althaus et al. 2014)
and to correlate with empathy-related questionnaire measures
(Groen et al. 2013; Althaus et al. 2014).
In agreement with the study by Jansen et al. (2006), we
expected that higher blood plasma OXT baseline levels would
be found in the group of male adults with ASD than in the
group of male controls. Furthermore, we explored whether
blood plasma OXT levels correlated with behaviour charac-
teristics as assessed by means of a variety of questionnaires.
We finally expected that males with lower blood plasma OXT
baseline levels would benefit more from exogenous OXT ad-
ministration and hence would show larger treatment effects.
This would be reflected by an enhancement of the ECR and
LPP responses to affective pictures with humans as compared
to pictures without humans after OXT intake. As OXT plasma
levels might be differentially related to centrally controlled
behaviour in autistic and healthy people (see Modahl et al.
1998; Green et al. 2001; and Jansen et al. 2006), we explored
whether the potentially moderating effects might differ for the
male adults with ASD and the healthy male adults by investi-
gating these effects in both groups separately.
Methods and material
The study had been approved by the Medical Ethics
Committee of the University Medical Center Groningen, and
written informed consent was obtained from all participants.
Most parts of the methods and material have been de-
scribed in more detail previously (Althaus et al. 2015). Yet,
the parts most essential to the present paper have been outlined
again below, completed by the description of OXT extraction
and analysis.
Participants
In total, there were n=61 participants in the age of 18–34 years
(M=22.67; SD=4.22). The patient group consisted of n=31
males with a Diagnostic and Statistical Manual of Mental
Disorders (DSM)-IV diagnosis of ASD, and the control group
included n=30 healthy male participants. The healthy partici-
pants were recruited by advertisements at schools and public
spaces. They all reported to be free from psychopathology, which
was confirmed by normal scores on the 90-item Symptom
Checklist (SCL-90, Arrindell and Ettema 1986). The patients
were recruited via our own outpatient clinic of the University
Center Child and Adolescent Psychiatry, Accare, and via the
Autism Team of the North of the Netherlands (ATN). The inclu-
sion criterion for the ASD patient group was the presence of a
DSM-IV-TR diagnosis in the autistic spectrum, i.e. autistic dis-
order, Asperger’s disorder or pervasive developmental disorder
not otherwise specified (PDD-NOS, American Psychiatric
Association 2004). For confirmation of the diagnosis established
by a well-trained psychiatrist, the patient needed to have a score
at or above the cutoff criterion for ASD on at least one of four
standardized measures: the Communication or Social Interaction
scale of the Autism Diagnostic Observation Scale (ADOS, Lord
et al. 2000), which had been assessed in part of the sample as part
of routine clinical care; the Social Responsiveness Scale for
Adults (SRS-A, Constantino et al. 2003), which was completed
by a good acquaintance of the participant; or the autism ques-
tionnaire (AQ, Baron-Cohen and Wheelright 2001) completed
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by the participant himself. Further inclusion criteria applying to
all participants were IQ≥80 as measured by the Groningen
Intelligence Test (GIT-2, Luteijn and Barelds 2005); normal or
corrected to normal vision, and being free from a nasal
congestion due to a cold or allergy at the day of testing.
Exclusion criteria for all participants were regular use of
psychotropic medication or having a history of alcohol or drug
abuse. All participants had to abstain from taking alcohol,
stimulants, ecstasy or soft drugs for 20 h, from caffeine for
4 h and nicotine for 2 h before the experiment.
The groups did not differ in age and intelligence.
Furthermore, participants completed a set of questionnaires
on autistic traits, empathic and social skills that were used
for correlational analyses (see section 2.5.3).
Procedure
Participants were invited for the experiment on two different
days, separated by 1 week. During the experiment, partici-
pants were asked to view a series of photographs (see section
2.3) while their EEG and ECG were recorded. On one of the
2 days, participants received a nasal spray with OXT, 24 IU
Syntocinon® (Sigma Tau), while on the other day, the nasal
spray contained placebo, a saline solution (8 mg/ml;
Pharmachemie, Haarlem, The Netherlands). The order of the
treatments was double-blind and randomized within the
groups. The experiment always took part at the same time of
the day; either participants started at about 9 am (n=15 con-
trols and n=11 males with ASD) or at about 2 pm (n=14
controls and n=20 males with ASD).
The procedure followed the time schedule depicted in
Fig. 1. Participants started with a check on the rules of absti-
nence and a brief questionnaire on state anxiety (Spielberger’s
State-Trait Anxiety Inventory, STAI; Spielberger 1973). This
was followed by a first venipuncture, with the tube being set
on ice and immediately brought to the laboratory. Then the
nasal spray was administered. After the experimenter primed
the spray, the participant self-administered the spray by
alternatingly puffing three times in each nostril (with 4 IU
Syntocinon per puff this resulted in 24 IU in total).
Participants were instructed to close one nostril and to ‘sniff-
like’ inhale the puff in the other nostril. After spraying, the
EEG and ECG equipment was applied by the experimenter
(30 min), and a practice block of viewing pictures was per-
formed by the participant (5 min). This was followed by a
second venipuncture, with the period between spraying and
the venipuncture lasting about 50 min (M= 53.13 min;
SD=4.92). The viewing of pictures started about 10 min later,
and lasted for 45 min. The period between spraying and
starting the task lasted about 60 min (M=60.33; SD=5.48).
After task completion, the EEG/ECG equipment was taken
off, and the participants completed some brief questionnaires
about potential side effects of the nasal spray, their experience
and motivation during the task, as well as their state of
comfort/anxiety (STAI).
IAPS Task
Participants watched a series of 414 photographs that had been
selected from the International Affective Picture System
(IAPS) (Lang et al. 2008), representing the following condi-
tions: neutral, positive or negative emotions in scenes with
humans (socially relevant conditions); or neutral, positive or
negative emotions in scenes without humans (socially irrele-
vant conditions, see Groen et al. (2013) or Althaus et al. (2014,
2015)). By using E-prime 2.0, the pictures were serially pre-
sented for 1 s with a variable inter-stimulus interval of 3 to 5 s
and required no response. The conditions were balanced and
presented in random order. To ensure attentive watching, par-
ticipants were instructed to press a button whenever a red-
white checkerboard appeared on the screen. These target stim-
uli appeared randomly in a target/picture ratio of 1:6. Picture
presentation was divided into three blocks of each lasting
about 13.5 min, separated by short breaks of a few minutes.
Data collection, preprocessing and dependent variables
Blood sampling and plasma OXT analysis
Blood samples were obtained using 10 ml EDTA tubes that
were immediately put on ice and centrifuged at 1500 g for
15 min within 1 hour after collection. To separate OXT from
Fig. 1 Time schedule of the
experiment
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its binding proteins, 300 μl HCl (0.5 M) was added to 1 ml of
EDTA plasma, and the mixture was prepurified by means of
Oasis HLB (1 ml, 30 mg) extraction cartridges. OXT was
eluted from the cartridges by 100 % methanol. The eluates
were evaporated in a Savant SpeedVac SC200, and 250 μl
phosphate buffer (Na2HPO4·2H2O containing 13 mM
EDTA, 0.02 % sodiumazide, 0.25 % BSA, 0.1 % Triton X-
100, pH 7.4) was added to the tubes. OXTwas quantified by
an in-house radioimmunoassay (RIA). In short, 50 μl poly-
clonal antibody (diluted 1:160,000) raised in rabbit was added
to 100 μl reconstituted sample and pre-incubated at 4 °C for
72 h. Then, 25 μl of 125I-labelled OXT (3000 dpm) was
added, and incubation was continued for 24 h. Bound and free
OXT were separated by a second antibody (10 % sheep anti-
rabbit IgG and 0.01 % rabbit IgG (carrier protein)/
polyethyleneglycol 6000 solution. Radioactivity in the tubes
(bound fraction) was counted using an automatic gamma-
counter (1470Wizard TMWallac, Turku, Finland). Data were
analysed with a four parameter fit program.
Recovery was determined by addition of synthetic OXT
(Sigma-Aldrich, cat. Nr O-6379) to plasma pools with 1.4
and 2.9 pmol/l endogenous OXT. The average recovery at
these two levels (n=5) was 78±6 %. Within- and between-
assay CVs were 11.1 and 12.8 % at 6.3 pmol/l. All samples
were measured in duplo. The synthetic OXT preparation was
used for radioiodination and for constructing a dose-response
curve. The RIA specifically detects OXT. Cross-reactivity
with arginine vasopressin, lysine-vasopressin and desamino-
D-arginine-vasopressin all were <0.01 % on mass basis. The
analytical sensitivity was 1.5 pmol/l. For statistical analysis of
the data, levels below the analytical sensitivity of the assay
were assigned a value of 50 % of this sensitivity.
ECG recording and pre-processing of the ECR
The participants’ ECGwas recorded from pre-cordial leads by
BrainRecorder (brain products) with a sample rate of 500 Hz.
For analysis of the ECRs, sequential interbeat intervals (IBIs)
occurring around each stimulus presentation were extracted
from the R-peak series. IBIs were extracted in segments of
1 s before stimulus onset to 4.5 s after stimulus onset, and
sampled every 0.5 s. This resulted in 12 IBI values for each
stimulus. For each participant, averages were computed for
each stimulus condition, with IBI0 referring to the IBI at stim-
ulus onset and with IBI-1 serving as the baseline value (i.e. the
IBI value at 1 s before stimulus onset was subtracted from all
successive IBI values). Finally, by using SPSS, for each par-
ticipant, the maximal cardiac deceleration was determined in
the interval from −0.5 to 4 s (IBIMAX). For the validity of this
measure, we refer to Althaus et al. (2014).
EEG recording and pre-processing of the LPP
EEG was also recorded by BrainRecorder from 61 scalp elec-
trodes that were placed according to the 10–20 system by
means of a lycra stretch cap (Electro-Cap Center BV). Based
on previous work, 34 electrode positions were selected for
analysis.
In the placebo condition, the LPP amplitude was
maximal over parietal electrode positions in the time
window of 400–1000 ms after stimulus onset, see
Fig. 2. To determine the electrode positions showing
the strongest task effects, we performed repeated mea-
sures analyses on the data from the control group with
the factors ‘hemisphere’, emotional ‘valence’ and pres-
ence of ‘humans’ on successive time intervals of
100 ms. We found that the largest effects of humans,
valence and their interaction were present at Pz, P3 and
P7 in the intervals running from 600 to 1000 ms.
Further analyses of the LPP were therefore performed
for the Pz, P3 and P7 potentials occurring in the inter-
val running from 600 to 1000 ms.
Statistical analyses
Group differences in OXT baseline and OXT
post-administration levels
As the two blood plasma values obtained before OXT
and placebo administration, respectively, did not differ
Fig. 2 Topographical maps of the
difference waves between
pictures with and without humans
in the interval 600–1000 ms after
stimulus onset. Maps refer to the
control group in the placebo
condition and show the activity
evoked by watching pictures with
humans as compared to pictures
without humans
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from each other, baseline OXT (BLOXT) levels were
computed by averaging these two values. This resulted
in a more stable measure with less variance. Post-
administration levels were adjusted for individual differ-
ences in pre-administration levels by subtracting the pre-
administration values from the post-administration values
(ΔOXT). All values were tested for group differences by
means of Student’s t tests for independent samples.
Differences between pre- and post-administration values
were tested by paired Student’s t tests.
To check whether the baseline levels (BLOXT) measured
in the morning would differ from those that were measured in
the afternoon and whether this would differ for the two groups
of participants, an ANOVAwas carried out with the between
subjects (BS) factors ‘group’ (controls vs. ASD) and ‘Time of
the Day’ (morning vs. afternoon).
Correlations between peripheral OXT levels and behavioural
measures
Pearson’s correlations were computed for both BLOXT and
ΔOXT with all of our behaviour measures including age,
intelligence and the questionnaire scores, which are summa-
rized in Table 1.
Treatment moderating effects of OXT baseline level: analyses
of co-variance
Treatment effects on the ERC (IBIMAX) and the three LPP
values referring to respectively, Pz, P3 and P7 were analysed
by a 2*2*3 repeated measure ANOVAwith the within subject
(WS) variables treatment (placebo vs. OXT), human (humans
vs. scenes), and valence (neutrals vs. positive vs. negative). To
investigate the treatment moderating effect of plasma OXT,
the variable BLOXT was entered as a covariate while focus-
sing on the interaction of the covariate with the treatment (by
task) effects. Analyses of covariance were carried out both on
the whole group and the two groups separately. For effects
with valence involved, Greenhouse-Geisser adjusted p values,
and the epsilon correction factors were reported. Planned com-
parisons were carried out by computing contrasts between
each of the three valence pairs. All data were controlled for
outliers being defined as z≤−3 and z≥3.
For all comparisons, next to the p values, Cohen’s d or
partial eta squared are presented as measures of effect size.
Rejection level was set at p= .05, but trend significant (p≤ .1)
findings were further elaborated if accompanied by medium
or high effect sizes.
Regression analyses and high vs. low plasma OXT group
comparisons
To investigate in which direction OXTeffects on the ECR and
LPP responses might have been moderated by plasma OXT,
we conducted regression analyses of the BLOXT values on
the treatment-dependent effect scores. To this end, the effects
of (1) human and (2) human*valence were translated into the
effect scores (delta values). For their exact computation, we
refer to our previous study (Althaus et al. 2015). In a final step
(trend), significant regressions, i.e. (trend) significant treat-
ment interactions with the covariate were further elaborated
by comparing groups with high vs. low BLOXT values on
their orienting responses in both the placebo and OXT condi-
tion. This comparison was conducted by a 2*2*3*2 ANOVA
design with the WS variables; treatment, human and valence
and the BS variable group formed on the basis of the 33.3th
and 66.6th percentiles of the BLOXT values.
Table 1 Relevant behaviour characteristics as measured by questionnaires
Questionnaire Authors and year Scales Measurement
Autism spectrum quotient (AQ) Baron-Cohen et al. 2001 AQ total Autistic traits






Empathy quotient (EQ) Baron-Cohen and
Wheelwright 2004
EQ total Empathic skills
Interpersonal Reactivity
Index (IRI)















Spielberger 1973 State anxiety
Trait anxiety
State and trait anxiety
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Results
Task effects, OXT treatment effects and group differences
in task and treatment effects
Both the ECR and LPP were larger in response to pictures
with humans and this held for in particular the affective pic-
tures. Yet, our study revealed no group difference and no
effects of the nasally administered OXT on the orienting re-
sponses. Nor did the groups differ in their treatment response.
For the statistical details and corresponding figures presenting
the ECR and LPP in placebo and OXT condition, we refer to
Althaus et al. (2015).
Group differences in BLOXT levels and correlations
of BLOXT levels with behaviour variables
First of all, morning values of BLOXT did not differ from
afternoon values [F(1,56)=0.16; p= .69], and this did not dif-
fer for the two study groups [F(1,56)=0.25; p= .61].
Table 2 summarizes group means and standard deviations
of the blood plasma OXT values obtained from the blood
samples taken before and after placebo and OXT administra-
tion of the control group and the group with ASD, respective-
ly. It shows that the groups differed significantly in their
values of the pre-treatment (placebo and OXT) situations with
small effect sizes, and in the values averaged across these
situations (BLOXT) withmoderate effect size. The males with
ASD showed significantly higher baseline OXT plasma con-
centrations than did the control males.
Large differences were found between the OXT levels be-
fore and after OXT administration [for the whole group: t
(59) = 11.95; p < .001; d = 1.55; controls: t (29) = 8.26;
p< .001; d=1.51; ASD: t (28)=8.67; p< .001; d=1.61], yet
groups did not differ in these ΔOXT levels [FTime*Group (1,
57)= .45; p= .51].
BLOXT did not correlate with any of the behaviour mea-
sures. It did, however, correlate significantly with the level of
intelligence in the whole group (r= .31; n=61; p= .02) and in
the group with ASD (r= .38; n=31; p= .04).
Baseline OXT level as moderator of the OXT treatment
effect
We found a significant interaction of BLOXT with the OXT
treatment effect on responses to pictures with humans (as
compared to the pictures without humans) for the ECR
[FTreatment*Human*BLOXT (1,27)=5.69; p= .024; η
2= .17] and
a trend significant interaction with medium effect size for
the LPP at Pz [FTreatment*Human*BLOXT (1,29)=3.35; p= .07;
η2= .10] in the group with ASD, but not in the control group.
However, the two groups did not differ significantly from each
other in this BLOXT-dependent response to the treatment
[ECR: F(1,27) = 1.22; p = .27; η2 = .02; LPP at Pz: F(1,
59)=2.53; p= .12; η2= .04]. For the LPP at P7, a significant
interaction was found for the whole group of participants
[FTreatment*Human*BLOXT (1,59)=3.96; p= .04; η
2= .06].
Regression of the BLOXT values upon the OXT effect on
the ECR response to pictures with humans shows that in the
group with ASD lower BLOXT values were associated with
smaller effects. The same holds for the regression of BLOXT
upon theOXT treatment effect on the LPP responses to human
pictures (Fig. 3a–c). For none of the orienting responses,
BLOXT-moderating effects were found in the placebo
situation.
Comparisons of the 33.3 %males (n=10) with ASD show-
ing the lowest BLOXT levels (≤0.90 pmol/l) with the 33.3 %
(n = 10) males showing the highest BLOXT levels
(≥1.74 pmol/l) resulted in a trend significant interaction of this
group variable with the treatment effect on the ECR response
t o h u m a n p i c t u r e s w i t h h i g h e f f e c t s i z e
[FTreatment*Human*BLOXTGroup (1,18) = 2.99; p= .1; η
2= .15].
Table 2 Group means and
differences in plasma OXT values Controls n = 30 ASD n = 31 Group differences
Mean (sd) Mean (sd) t (df) p d
OXTa before PLb 0.66 (0.93) 1.50 (2.07) −1.96 (59) .05 0.39
OXT after PLb 0.80 (1.33) 0.83 (0.95) −0.89 (59) >.1 0.23
OXT before OXTc 0.67 (0.94) 1.32 (1.67) −2.37 (59) .02 0.47
OXT after OXTc 9.88 (6.34) 9.60 (5.04) 0.19 (57)d >.1 0.05
BLOXT 0.67 (0.77) 1.34 (1.05) −2.85 (59) .006 0.73
ΔOXT 9.20 (6.10) 8.22 (5.11) 0.67 (57)d >.1 0.17
a Plasma OXT measured in pmol/l
b, c Placebo/OXT administration
d There were two missing values in the ASD group
BLOXT: mean value of OXT concentrations before placebo and oxytocin administration. ΔOXT: OXT after
OXTc minus OXT before OXTc
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For the LPP at Pz, comparison of the two groups revealed a
s i g n i f i c a n t t r e a t m e n t b y g r o u p i n t e r a c t i o n
[FTreatment*Human*BLOXTGroup (1,18)= 4.30; p= .05; η
2= .19],
and for the LPP at P7, when comparing the 33.3 % (n=20)
participants of the whole group showing the lowest BLOXT
values (≤0.49 pmol/l) with the n=20 participants showing the
highest BLOXT values (≥1.38 pmol/l), a significant group
interact ion wi th the t reatment effect was found
[FTreatment*Human*BLOXTGroup (1,38)=6.12; p =. 02; η
2= .14].
The interactions are plotted in Fig. 4a–c.
Summarizing the moderating influence of baseline OXTon
the OXT treatment effects, we found that, opposite to what
was expected, males with higher plasma OXT concentrations
showed larger OXT treatment effects as expressed by an en-
hancement of their ECR and LPP responses to pictures with
humans during OXT intake as compared to the placebo situ-
ation. This was found in particular for the males with ASD.
An illustration of this OXT administration-induced enhanced
orienting to pictures with humans in only the high baseline
OXT group is given in Fig. 5 showing the LPP response at Pz,
which discriminated the two groups of ASD participants with,
respectively, low and high BLOXT values from each other
with high effect size.
Additional analyses
To obtain more insight into the mechanisms of how peripheral
OXT levels may influence OXT administration- induced cen-
tral effects, we investigated whether plasma OXT levels
assessed after nasal OXT administration would be related to
the effects of nasal OXT administration on social orienting. If
larger peripheral post-administration levels were found to be
associated with greater OXT treatment effects, this would
suggests a parallel increase of peripheral and central levels
after nasal OXT administration. If, however, larger post-
administration plasma levels were associated with smaller
treatment effects, this might suggests that less OXT had be-
come centrally active due to, for example, leakage, less ab-
sorption or central saturation. Analyses were carried out on the
baseline-adjusted post-administration levels (ΔOXT).
Regression of the post-administration values upon the
OXT effect on the ECR responses to pictures with humans
Fig. 3 Regression of the baseline OXTconcentrations upon the treatment effect on the orienting responses ECR (a), LPP at Pz (b) and LPP at P7 (c) to
pictures with humans as compared to pictures without humans in male adults with ASD
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Fig. 4 Means and SEMs of the human effect illustrating the increase of the orienting responses ECR (a), LPP at Pz (b) and LPP at P7 (c) to pictures with
humans in the OXT condition for only the ASD males with high baseline levels of blood plasma OXT
Fig. 5 ERPs (LPP at Pz) in response to pictures with andwithout humans of ASDmales having low (≤P33) and high (≥P66) blood plasmaOXT baseline
values
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showed that in the whole group of participants lower ΔOXT
values were associated with larger effects (c=6.21, ß=−.30;
n=61; t=−2.34; p= .02). The same was found for the regres-
sion of the OXT treatment effect on the LPP Pz response to
negative human pictures, yet in only the control group
(c=2.10, ß=−.36; n=30; t=−2.02; p= .05) and the regres-
sion on the LPP P7 response to human pictures (c=0.78,
ß=−.43; n=30; t=−2.49; p= .02) again in only the control
group (see Fig. 6a–c). Moreover, a significant positive associ-
ation was found between ΔOXT and the LPP P7 response to
pictures with humans in the placebo situation (c= - 0.16,
ß= .48; n=30; t=2.95; p= .006; see Fig. 6d).
Summarizing the association of post-administration pe-
ripheral OXT with the OXT treatment effects, we found that
individuals with low post-administration values showed an
enhancement of their social orienting after OXT intake while
those with high post-administration levels showed a decrease.
Figure 7a, b illustrates the OXT administration-induced en-
hanced orienting to pictures with humans as is assessed by
the LPP at P7 in only the low level (≤P33) post-
administration OXT group, which differed significantly from
the high level (≥P66) post-administrat ion group
[FTreatment*Human*Valence(negative)*ΔOXTGroup (1,18) = 4.70;
p= .04; η2= .21]. The figures moreover show the significant
difference between the groups in their placebo responses to
pictures with humans.
Discussion
The present study investigated whether OXT treatment effects
on social orienting are moderated by blood plasma OXT levels.
We first investigated whether there were any correlations be-
tween the plasma OXT levels and a variety of personality char-
acteristics and behaviour problems as measured by question-
naires. No significant correlations were found, not even for the
previously found OXTeffect-moderating personality character-
istics that were related to coping with social stress, anticipation
Fig. 6 Regression of the baseline-adjusted post-administration
OXT concentrations upon the treatment effects on the orienting
responses ECR (a), LPP at Pz (b), LPP at P7 (c) to (negative,
Pz) pictures with humans and upon the LPP P7 orienting responses
in the placebo situation (d)
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of punishment and criticism or the drive for goal achievement
(see Althaus et al. 2015). This corresponds with the findings by
Jansen et al. (2006) who also did not find plasma OXT baseline
levels to be correlated with any of their measures assessing
autism- and anxiety-related behaviour in high-functioning
adults with ASD or healthy controls.
Also in agreement with the study by Jansen et al. (2006),
yet in contrast to what has been found in children with ASD
(Modahl et al. 1998; Green et al 2001), is our finding that our
group of ASD male adults had significantly higher baseline
plasma OXT levels than our male adult control group. The
difference with the findings in children was explained by
Jansen and colleagues as being due to their sample consisting
of intellectually high-functioning adults with ASD suggesting
both developmental and intellectual factors playing a role in
the increased OXT plasma levels. The suggestion of intellec-
tual functioning being associated with OXT plasma levels in
individuals with ASD is supported by the positive correlation
we found between baseline plasma OXT and the level of in-
telligence in our high-functioning ASD group. This group,
though not differing in mean IQ from our control group,
showed significantly greater variance (Leven’s test: F=8.14;
p < .006) caused by several very high IQ scores (n = 7:
IQ>120). Considering that only the ASD participants with
high baseline OXT levels showed an increase in their social
orienting responses after OXT administration, and that base-
line OXT levels were positively correlated with IQ, we inves-
tigated whether intelligence would be a moderator of the OXT
administration effect but did not find so. Therefore, IQ seems
to be functionally related to the baseline plasma OXTconcen-
trations but not to the effect of exogenously administered
OXT on social orienting.
The seemingly counterintuitive finding of male adults with
ASD having higher plasma concentrations of OXT corrobo-
rates not only the finding by Jansen et al. (2006) but also those
of several other studies. Higher plasma concentrations were
Fig. 7 ERPs at P7 in response to pictures with andwithout humans of the
control males having low (≤P33) and high (≥P66) post-administration
blood plasma oxytocin values, respectively (a). Means and SEMs of the
human effect illustrating the increase of the social orienting response in
the OXT condition for only the males with low levels of post-
administration blood plasma OXT. The graph also demonstrates the
group differences in the placebo situation (b)
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also found in males with a major depression (MD) as com-
pared to females with MD as well as to healthy male controls
(Yuen et al. 2014). This gender dependency proves how im-
portant it is to take into account sex differences when studying
the role of OXT in psychopathological conditions. Plasma
concentrations were also shown to positively correlate with
fear of romantic attachment in healthy (predominantly female)
individuals (Marazziti et al. 2006) and with the severity of
social anxiety and dissatisfaction with social relationships in
male and female patients with a Generalized Social Anxiety
Disorder (GSAD) (Hoge et al. 2008). Higher plasma OXT
concentrations are hence not unique to male adults with
ASD and are suggested to go along with social anxiety-
related problems.
OXT release into the peripheral circulation, however, may
depend on what happens shortly before and/or during blood
collection. As both physical and psychological stress have
been suggested to activate the hypothalamic-pituitary-
adrenocortical (HPA) axis and as neuroendocrine stress re-
sponses have been characterized by, among others, OXT re-
lease from the pituitary gland into the peripheral circulation
(e.g. Onaka 2004), one might argue that the venipunctures
were more stressful to our ASD participants than to the control
males leading to larger OXT releases into the bloodstream.
There are several arguments which may weaken this hypoth-
esis. In the studies by Modahl et al. (1998) and Green et al.
(2001), childrenwith ASDwere involved showing lower plas-
ma concentrations although they had undergone venipuncture
as well. The present study included only participants with
ASD who had indicated not to be afraid to undergo two veni-
punctures. Furthermore, no correlations were found between
the decrease in OXT concentration and the decrease in the
state anxiety measures obtained in the placebo situation, al-
though the latter was shown to be significant in both groups
(Althaus et al. 2015). If the punctures had been more stressful
to the males with ASD leading to more peripheral OXT re-
lease, we would have expected a significant correlation be-
tween the decrease in STAI scores and plasma levels in the
placebo situation, especially in the group of males with ASD.
Still more intriguing than the higher OXT baseline level
found for the males with ASD is our finding that OXTadmin-
istration effects on social orienting were moderated by periph-
eral OXT baseline concentrations. This moderation was oppo-
site to what we had expected according to the literature.
Assuming that the reported positive correlations of peripheral
OXT levels with centrally controlled prosocial behaviour (e.g.
Feldman et al. 2007; Strathearn et al. 2009) and negative cor-
relations with psychopathological symptoms (e.g. Rubin et al.
2010; Skrundz et al. 2011) implicate that plasma OXT con-
centrations are reflective of intra-cerebral OXTconcentrations
and activity, we inferred a greater benefit from exogenously
administered OXT in individuals with low peripheral levels of
OXT. Yet, high levels of baseline plasma OXTwere found to
be associated with beneficial effects of nasally administered
OXT on social orienting, while low levels were accompanied
by a decrease in the orienting responses when OXT was ad-
ministered. Figure 4 shows that the differences between indi-
viduals with high and low baseline plasma levels refer to the
social orienting responses in only the OXT condition. Our
findings therefore suggest that peripheral baseline OXT levels
are predictive of the effects of extraneously administered OXT
on centrally controlled social orienting but not of social
orienting itself.
As the OXT treatment effects turned out to be beneficial in
those who have higher baseline peripheral levels, we speculate
that a high peripheral level might be indicative of an initially
lower central baseline level which is likely to be enhanced by
nasal administration of OXT. While the lacking correlations
between plasma and CSF levels of OXT reported by Takagi et
al. (1985), Winslow et al. (2003), Altemus et al. (2004), and
Kagerbauer et al. (2013) have been supposed to reflect disso-
ciated peripheral and central OXT release patterns, the
positive correlations between absolute central and blood
plasma peak values after nasal administration found in rats
by Neumann et al. (2013) suggest the opposite. These find-
ings, however, do not contribute to explain the direction in
which we found the plasma baseline levels being associated
with the central effects of nasally administered OXT. Might
our findings on the associations of the treatment effects with
the post-administration level shed some more light on the
relationship between plasmaOXT levels and the susceptibility
to extraneously administered OXT? First, we found a signifi-
cant and about tenfold increase of the plasma OXT values
about 53 min (±SD = 4.92) after nasal administration.
Adjusted for pre-administration values, these increases did
not differ between our two groups of healthy male adults
and male adults with ASD, neither in their absolute values,
nor in their values relative to baseline. We further found that
individuals with high post-administration OXT plasma levels
showed decreased social orienting after OXT intake. This was
assumed to be observed if higher peripheral post-
administration levels reflect that less OXT had become cen-
trally available or active due to leakage, less absorption or
central saturation. Whereas intranasal applications of OXT
have been shown to result in very large increases in circulating
OXT i.e. to levels far above those that are needed for physio-
logical effects, only small amounts may enter the brain while
penetrating some specific brain regions yet not entering the
CSF (Leng and Ludwig 2016; Neumann et al 2013). This may
be due to leakage that has been suggested indeed to occur as a
consequence of intranasal spray delivery. In studies on ma-
caques, comparing nasal spray administration with OXT neb-
ulizer delivery, a significant and similar elevation of CSF
OXT levels was found for both delivery methods while plas-
ma OXT was significantly enhanced only after intranasal ad-
ministration (Dal Monte et al. 2014; Modi et al. 2014). The
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authors explained the significant elevation of plasma OXT by
the possible formation of larger droplets from the spray, which
would rest on the nasal mucosa and hence provide for vascular
absorption as compared to the nebulizer forming a much finer
mist and allowing more of the substance to be breathed in
deeper towards the epithelium.
Yet, post-administration levels were not only related to the
treatment effects (see Fig. 7a, b) but also to the social orienting
responses in the placebo situation. The groups with low and
high post-administration plasma levels differed in their ECR
and LPP P7 responses to pictures with humans in especially
the placebo situation (LPP at P7: t=2.19; df = 18; p= .04;
ECR: t=1.8; df=36; p= .08), which means that the groups
differing in their post-administration OXT plasma levels also
differ in their pre-administrative social orienting responses
that are centrally controlled because they demand the evalua-
tion of information as being relevant or not. This cannot be
explained by differences in leakage of the administered OXT
from the nasal mucosa into the bloodstream but might agree
with the above proposed hypothesis of individual differences
in central absorption being due to differences in central bio-
availability. Individuals with lower post-administration plas-
ma concentrations might have had an initially decreased
central availability of OXT with the consequence that more
of the OXT administered became centrally active while less
was released into the peripheral bloodstream.
The study included only males with an IQ≥80, with seven
males of the ASD group having an IQ of even ≥120. This
confines generalizability of our findings to a subgroup of only
high-functioning males with ASD. As IQ was found to corre-
late with baseline OXT plasma concentrations in this group,
OXT studies with low functioning individuals with ASD are
warranted.
The number of participants was too small to enter multiple
covariates into the design in order to investigate the potential
interactive moderating of OXTeffects by OXT baseline levels
and the previously found questionnaire-assessed behaviour.
Yet, for the behaviour that was previously found to moderate
the effects of OXT on social orienting, no correlations were
found with OXT baseline levels.
The findings on the OXT moderations cannot be
interpreted as unambiguously specific to the two groups in-
vestigated, i.e. the findings on baseline OXT plasma concen-
tration as moderating the treatment effect in only the males
with ASD and the findings on post-treatment OXTconcentra-
tions as moderating the treatment effect in only the control
group since group differences were not found to be
significant.
Yet, from the findings of the present study, we can conclude
that plasma OXT levels are associated with the effects of na-
sally administered OXT on social orienting as assessed by
neurophysiological responses to socially relevant information.
As our findings were rather unexpected, their interpretation is
a tentative one; we propose that it is the central availability of
OXT that determines how much of the nasally administered
OXT will become absorbed and centrally active, and how
much of it will become released into the bloodstream. Yet,
still too little is known about the relationship between periph-
eral and central OXT concentrations on the one hand and
peripheral concentrations and the central action of exogenous-
ly administered OXTon the other hand. This holds for healthy
individuals as well as for individuals with a psychopatholog-
ical condition and means that both more preclinical and clin-
ical studies are warranted. Preclinical studies might, for exam-
ple, compare OXT plasma and CSF or local brain OXT con-
centrations after both nasal administration and intracerebro-
ventricular (ICV) infusion while at the same time investigat-
ing social behaviour. This has, to the best of our knowledge,
not yet been done but would be an extension of, for example,
the studies by Calcagnoli et al. (2015a, b) who compared the
effects of ICV with intranasal OXT administration on
aggressive and prosocial behaviour in rats but did not
analyse plasma OXT concentrations, and by Neumann et al.
(2013) who compared changes in central and peripheral OXT
concentrations after nasal and intraperitoneal administration
but did not relate these concentrations to central effects, i.e.
to changes in social behaviour. Clinical studies on the effects
of exogenous OXT administration (preferably by nasal spray)
should more and more take into account peripheral OXT
levels as a potential treatment moderator.
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